--- title: "Crawford Investment 13F (2026 Q1): An Income-and-Quality Book" type: research slug: crawford-investment-counsel-13f-2026-q1 canonical_url: https://13finsight.com/research/crawford-investment-counsel-13f-2026-q1 published_at: 2026-05-24T10:08:50.776Z updated_at: 2026-05-24T10:08:53.489Z author: Marcus Chen author_title: Senior Market Analyst author_url: https://13finsight.com/authors/marcus-chen word_count: 455 locale: en source: 13F Insight --- # Crawford Investment 13F (2026 Q1): An Income-and-Quality Book > Crawford Investment Counsel builds around high-quality companies that pay and grow reliable dividends. Its 2026 Q1 book spreads $5.85B across 300 income payers, with a utility-and-staples backbone, AbbVie, AstraZeneca, AEP, Philip Morris, and a new AstraZeneca stake. Income and quality, spread wide Crawford Investment Counsel, an Atlanta firm with a long heritage in dividend-oriented investing, builds portfolios around a simple premise: high-quality companies that pay and grow reliable dividends tend to reward patient owners while cushioning the ride. Its 2026Q1 13F reflects that approach, about $5.85 billion spread across roughly 300 positions, with a sector mix tilted toward the dependable income payers, healthcare, utilities, consumer staples, and financials. The book is deliberately diffuse: the largest holding, AbbVie, is just 3.29% of reported value, and the rest of the top names sit between 2% and 3%. The roster pairs quality with yield. Microsoft and Johnson Controls sit near the top alongside AstraZeneca, regulated utilities American Electric Power and WEC Energy, consumer-staples stalwart Philip Morris, regional bank PNC Financial, Coca-Cola, and defense contractor RTX. These are the kinds of stable, cash-generative businesses that can sustain and raise dividends through a cycle, the raw material of an income-and-quality strategy. A utility-and-staples backbone What distinguishes an income-focused book from a pure growth or deep-value one is its sector skeleton. Crawford's lean toward regulated utilities (American Electric Power, WEC Energy), consumer staples (Philip Morris, Coca-Cola), and large healthcare (AbbVie, AstraZeneca) is characteristic: these sectors offer the predictable cash flows and dividend reliability that income investors prize, even if they rarely produce explosive growth. The breadth, 300 names with nothing above 3.3%, reinforces the conservative posture, spreading income across many payers rather than concentrating in a few. Measured activity, including a new AstraZeneca stake The quarter's moves were incremental, fitting a steady income strategy. Crawford established a new position in AstraZeneca that immediately ranked among its top holdings, adding a major pharmaceutical name to the healthcare sleeve. It trimmed Coca-Cola and RTX by about 10% and 7% of shares respectively, and pared Johnson Controls modestly, while holding the bulk of the utility and staples core flat. The pattern, adding a quality pharma payer while taking a little off two names that had run, is the gentle rebalancing typical of a dividend-and-quality manager rather than a decisive shift in strategy. How to read an income-and-quality book With 300 positions and no dominant bet, Crawford's filing is about the aggregate posture, not any single name. The signal lives in the sector composition, heavy in utilities, staples, healthcare, and financials, the natural home of dependable dividends, and in the measured direction of the changes, such as the new AstraZeneca stake. For investors who value income and downside resilience over maximum growth, a book like this serves as a vetted map of where a dividend-focused manager currently finds quality and yield together. You can explore the full holdings, the position changes, and the longer history on the Crawford Investment Counsel filer page. ## FAQ ### What is Crawford Investment Counsel's strategy? Crawford, an Atlanta firm with a long dividend-investing heritage, builds portfolios around high-quality companies that pay and grow reliable dividends. The result is a diffuse book tilted toward dependable income payers in healthcare, utilities, staples, and financials. ### What are Crawford's largest holdings in 2026 Q1? The top positions were AbbVie (3.29%), Microsoft (2.87%), Johnson Controls (2.74%), AstraZeneca (2.51%), and American Electric Power (2.27%), followed by WEC Energy, Philip Morris, PNC Financial, Coca-Cola, and RTX. ### Why does Crawford hold so many utilities and staples? Regulated utilities and consumer staples offer the predictable cash flows and dividend reliability income investors prize. Crawford's lean toward these sectors, plus large healthcare, is characteristic of an income-and-quality strategy focused on dependable payouts. ### What did Crawford change in 2026 Q1? It established a new AstraZeneca position that immediately ranked among its top holdings, trimmed Coca-Cola by about 10% and RTX by 7%, and pared Johnson Controls modestly, while holding the utility and staples core largely flat. ### How concentrated is Crawford's portfolio? Not at all. The roughly $5.85 billion book holds about 300 positions with the largest just 3.29% of value, spreading income across many payers in a conservative, diffuse posture rather than concentrating in a few names. ### How should I read an income-and-quality filing? Focus on the aggregate posture, not any single name. The signal lies in the sector composition, heavy in utilities, staples, healthcare, and financials, and in measured changes like a new AstraZeneca stake, showing where a dividend-focused manager finds quality and yield together. --- Source: 13F Insight — https://13finsight.com/research/crawford-investment-counsel-13f-2026-q1 Author: Marcus Chen — https://13finsight.com/authors/marcus-chen Last updated: 2026-05-24T10:08:53.489Z